Gastrointestinal stromal tumours: origin and molecular oncology.
about
Syndromic gastrointestinal stromal tumorsTargeted therapy of gastrointestinal stromal tumoursSomatic DNA mutation analysis in targeted therapy of solid tumoursClinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysisRare Tumors in Children: Progress Through Collaboration15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisSmall intestinal gastrointestinal stromal tumor in a young adult woman: a case report and review of the literaturePrimary gastrointestinal stromal tumors: Current advances in diagnostic biomarkers, prognostic factors and management of its duodenal locationHyperplasia of interstitial cells of cajal in sprouty homolog 4 deficient miceStructural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal regionA potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinasesIntegrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumorsA nomogram to predict disease-free survival after surgical resection of GISTPeripheral blood mononuclear CD133 mRNA levels correlates with response to treatment in patients with gastrointestinal stromal tumorsClinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.Endoscopic full-thickness resection and laparoscopic surgery for treatment of gastric stromal tumors.Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review.In vivo fluorescence imaging of gastrointestinal stromal tumors using fluorophore-conjugated anti-KIT antibodyHigh-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.Endoscopic full-thickness resection for gastric submucosal tumors arising from the muscularis propria layer.Allosteric communication across the native and mutated KIT receptor tyrosine kinase.Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas.Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.Cellular expression profile for interstitial cells of cajal in bladder - a cell often misidentified as myocyte or myofibroblast.Dystrophin is a tumor suppressor in human cancers with myogenic programs.Upregulation of Atoh1 correlates with favorable survival in gastrointestinal stromal tumor.Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Succinate dehydrogenase-deficient gastrointestinal stromal tumors.Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.HER4 is a novel prognostic biomarker in gastrointestinal stromal tumor specifically originated from stomach.Gastrointestinal stromal tumor - an evolving concept.Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy
P2860
Q26738882-83E2C94C-A2A6-4CDA-B2E1-AACA0A693263Q26745633-FBB53A88-DDBC-4E6D-95FF-5179736301DBQ26770324-91A961FF-0840-4592-9FF2-AF2B68E25F5CQ26782641-F60B9E5E-D0BF-4E2B-B819-6883B4626572Q26797511-28C1D4D7-E5EC-440C-ABCD-2B5B3376B77BQ26798384-B4D680A1-F8E1-4C96-9E33-3E034463986BQ26800005-67B92A55-44D8-41A6-8189-94E358243FCCQ26825790-C40D7781-401D-4380-AF11-E4594C74A60DQ26829970-3563D893-B002-4122-8893-E4D89D0119A1Q27308910-D72CD252-F320-41EB-90E3-67D0D4902591Q27680371-471438AD-910C-4FCF-A7A8-682963DD46B2Q27851995-F01C02AD-05DE-4283-8F6F-7D52BA118F32Q28270556-BEF84AD0-579D-4DA7-96E3-A21520530E72Q28602517-8905F564-5186-41E9-AF06-2F761D8AD25DQ30366151-C8AFCCFB-2900-4BC1-AE23-48B934721365Q31110927-7C4FD5D7-744F-4D90-8A0C-4645FFDA075DQ33602552-46ECE12C-930B-4DE0-86A7-A3226F8B8BECQ33807742-739BE677-463C-4967-9848-CD2CBC2974F0Q33840444-BA3FCF3C-72AA-44E9-B0AD-E25D81A2175DQ33845604-35B29448-C8FD-4C6A-B73D-47D2C1ECEE93Q33954761-97AB48BE-4034-44FC-93D0-F5B5B2F54C12Q34024845-4D29DBF4-2982-46E0-A210-707E13282A95Q34283282-A16EF027-0A05-404D-8213-98AFE3FD9F3BQ34289180-FC121A7E-7DB1-4A2D-BF2A-D2157FF2CECAQ34326706-C4C5DBAD-CA64-4AF8-B660-8292632810B0Q34395251-1F8B3B4A-95F9-49A9-BABC-C43FEE1F878DQ34399597-E7AA951A-4164-4C46-9539-156D76A50697Q34407270-EFFFE24A-FCFE-45B3-A447-C98ADD1F83C4Q34473700-A999156E-DC92-4236-8920-B464EEB5858AQ34479070-5F943F2A-1FA2-4C82-BBE7-009C5A2513C3Q34501902-952ACBBE-A0DE-41D5-B78F-A91B80EA7FF2Q34518436-78E33161-BA0A-48BA-BFB2-47E0FC9FD425Q34645665-B83D93F5-7047-47E6-B37C-F1F3C0C82FF8Q34656740-96979A78-0AF3-461A-9431-2B326414F06FQ34662946-CBCC7DCC-6CA1-43B9-A89E-619D0CF59692Q34668378-42730072-8C5D-4A2B-B21B-CECAB592E41CQ34670665-23F4A500-5947-434F-BED3-FB443F0C1D1CQ34704954-9B60F1A6-0758-439B-8C22-7ABEE0EBBC0CQ34928165-4F2CBFE2-0210-4615-9791-44C13D0E5727Q34978826-EA3E8235-AB55-4A33-A6AD-3E5EDA77481E
P2860
Gastrointestinal stromal tumours: origin and molecular oncology.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Gastrointestinal stromal tumours: origin and molecular oncology.
@ast
Gastrointestinal stromal tumours: origin and molecular oncology.
@en
Gastrointestinal stromal tumours: origin and molecular oncology.
@nl
type
label
Gastrointestinal stromal tumours: origin and molecular oncology.
@ast
Gastrointestinal stromal tumours: origin and molecular oncology.
@en
Gastrointestinal stromal tumours: origin and molecular oncology.
@nl
prefLabel
Gastrointestinal stromal tumours: origin and molecular oncology.
@ast
Gastrointestinal stromal tumours: origin and molecular oncology.
@en
Gastrointestinal stromal tumours: origin and molecular oncology.
@nl
P356
P1476
Gastrointestinal stromal tumours: origin and molecular oncology
@en
P2093
Christine M Barnett
Christopher L Corless
P2888
P304
P356
10.1038/NRC3143
P407
P577
2011-11-17T00:00:00Z
P5875
P6179
1020858724